Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


04.02.2019

1 Am J Hematol
6 Blood
1 Bone Marrow Transplant
2 Br J Haematol
2 Haematologica
1 Int J Radiat Oncol Biol Phys
2 J Am Acad Dermatol
1 Lancet Oncol
7 Leuk Lymphoma
3 N Engl J Med
1 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. HONG H, Huang H, Fang X, Wang Z, et al
    A prognostic index for nasal-type early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Am J Hematol. 2019 Jan 28. doi: 10.1002/ajh.25426.
    PubMed     Text format    


    Blood

  2. LINDAHL LM, Besenbacher S, Rittig AH, Celis P, et al
    Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study.
    Blood. 2018;131:759-770.
    PubMed     Text format     Abstract available

  3. BRAUE JA, Daniels AB, Zwerner JP, Kim SJ, et al
    Intraocular involvement of mycosis fungoides associated with immunophenotypic switch from CD4(+) to CD8<sup/>.
    Blood. 2018;131:932-935.
    PubMed     Text format    

  4. MOSHREF RAZAVI H, Hrynchak M
    Unusual presentation of Burkitt-like lymphoma with 11q aberration in an elderly patient.
    Blood. 2019;133:381.
    PubMed     Text format    

  5. MARTIN P, Bartlett NL, Blum KA, Park S, et al
    A phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Blood. 2019 Jan 28. pii: blood-2018-11-886457. doi: 10.1182/blood-2018-11-886457
    PubMed     Text format     Abstract available

  6. VON HOFF L, Kargel E, Franke V, McShane E, et al
    Autocrine LTA signaling drives NF-kappaB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.
    Blood. 2019 Jan 29. pii: blood-2018-08-871293. doi: 10.1182/blood-2018-08-871293
    PubMed     Text format     Abstract available

  7. CASULO C, Barr PM
    How I treat early relapsing follicular lymphoma.
    Blood. 2019 Jan 30. pii: blood-2018-08-822148. doi: 10.1182/blood-2018-08-822148
    PubMed     Text format     Abstract available


    Bone Marrow Transplant

  8. ABUELGASIM KA, Alzahrani M, Alsharhan Y, Khairi M, et al
    Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma.
    Bone Marrow Transplant. 2019 Jan 30. pii: 10.1038/s41409-019-0454.
    PubMed     Text format    


    Br J Haematol

  9. BARTH MJ, Minard-Colin V
    Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 30. doi: 10.1111/bjh.15783.
    PubMed     Text format     Abstract available

  10. PACZKOWSKA J, Soloch N, Bodnar M, Kiwerska K, et al
    Expression of ELF1, a lymphoid ETS domain-containing transcription factor, is recurrently lost in classical Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 25. doi: 10.1111/bjh.15757.
    PubMed     Text format     Abstract available


    Haematologica

  11. TARANTELLI C, Zhang L, Curti E, Gaudio E, et al
    The BTK inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Haematologica. 2019 Jan 24. pii: haematol.2018.214759.
    PubMed     Text format    

  12. TOROSSIAN A, Broin N, Frentzel J, Daugrois C, et al
    Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
    Haematologica. 2019 Jan 24. pii: haematol.2017.181966.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  13. VARGO JA, Ward MC, Caudell JJ, Riaz N, et al
    A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Apr 24. pii: S0360-3016(17)30821.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  14. KHETERPAL MK, Dai J, Geller S, Pulitzer M, et al
    Role of imaging in low grade cutaneous B-cell lymphoma presenting in the skin.
    J Am Acad Dermatol. 2019 Jan 28. pii: S0190-9622(19)30144.
    PubMed     Text format     Abstract available

  15. DAMASCO FM, Geskin L, Akilov OE
    Onychodystrophy in Sezary syndrome.
    J Am Acad Dermatol. 2018;79:972-973.
    PubMed     Text format    


    Lancet Oncol

  16. GOURD E
    Promising new second-line therapy for Hodgkin lymphoma.
    Lancet Oncol. 2019 Jan 24. pii: S1470-2045(19)30016.
    PubMed     Text format    


    Leuk Lymphoma

  17. SCHAFFER M, Chaturvedi S, Davis C, Aquino R, et al
    Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
    Leuk Lymphoma. 2018;59:931-940.
    PubMed     Text format     Abstract available

  18. CASTANEDA C, Minton N, Mezo M, Hirsch D, et al
    False-positive pregnancy tests in females of reproductive potential receiving lenalidomide in the United States.
    Leuk Lymphoma. 2018;59:1025-1026.
    PubMed     Text format    

  19. VIDAL L, Lando S, Vaxman I, Shochat T, et al
    The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL - comparative study.
    Leuk Lymphoma. 2018;59:904-910.
    PubMed     Text format     Abstract available

  20. GOLDSCHMIDT N, Horowitz NA, Hefetz V, Darawshy F, et al
    Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
    Leuk Lymphoma. 2019 Jan 28:1-9. doi: 10.1080/10428194.2018.1564823.
    PubMed     Text format     Abstract available

  21. MARCHESELLI R, Franceschetto A, Sacchi S, Bari A, et al
    The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis.
    Leuk Lymphoma. 2019 Jan 28:1-7. doi: 10.1080/10428194.2018.1564049.
    PubMed     Text format     Abstract available

  22. KAHL BS, Dreyling M, Gordon LI, Martin P, et al
    Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
    Leuk Lymphoma. 2019 Jan 30:1-13. doi: 10.1080/10428194.2019.1571205.
    PubMed     Text format     Abstract available

  23. SALLES GA, Pettengell R, Cordoba R, Dlugosz-Danecka M, et al
    Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review.
    Leuk Lymphoma. 2019 Jan 31:1-16. doi: 10.1080/10428194.2018.1564828.
    PubMed     Text format     Abstract available


    N Engl J Med

  24. LI Y
    CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
    N Engl J Med. 2019;380:497.
    PubMed     Text format    

  25. VALERIUS T, Rosner T, Leusen JHW
    CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
    N Engl J Med. 2019;380:496-7.
    PubMed     Text format    


  26. CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
    N Engl J Med. 2019;380:496-498.
    PubMed     Text format    


    PLoS One

  27. WANG H, Zhou LY, Guan ZB, Zeng WB, et al
    Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis.
    PLoS One. 2019;14:e0210943.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  28. TAGAWA T, Gao S, Koparde VN, Gonzalez M, et al
    Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA.
    Proc Natl Acad Sci U S A. 2018 Nov 19. pii: 1816183115.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: